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Imported Schistosomiasis  
J. Uberos and A. Jerez-Calero 
Pediatrics Service, Universitary Hospital “San Cecilio”, Granada 
Spain 
1. Introduction 
Schistosomiasis is a parasitic disease caused by a trematode helminth of the genus 
Schistosoma. Of the latter, only six species affect humans: S. haematobium, S. mansoni  S. 
japonicum S. intercalatum, S. mekongi and S. malayensis. It is also termed bilharziasis, after its 
discoverer, the German doctor Theodor Maximilian Bilharz. In 1851, during his work at the 
Egyptian Department of Hygiene, he discovered this new class of helminth in the vena cava 
blood of patients who had died of haematuria.  
2. Biological cycle of the genus schistosoma 
Schistosoma has a cylindrical body, ending in two oral suckers. The adult forms are 
hematophagous, and are found in the venous plexuses, especially the mesenteric or 
perivesical, in the definitive host, where the male-female pairing takes place. The female 
migrates to the capillaries and venules, where 100-1000 eggs a day may be deposited. These 
eggs, in turn, migrate through the walls of the vessels in which they were deposited, 
reaching the tissues and then either the intestinal lumen or the urinary bladder lumen. 
Finally, they emerge in the faeces or the urine, respectively. There are two main forms of 
schistosomiasis: intestinal and urogenital. Among the species that parasitise humans, only S. 
haematobium affects the urogenital apparatus, with the other species normally producing 
intestinal parasitisation. 
Transported in the faeces or urine, the embryo eggs contaminate stagnant water in rivers, 
lakes and irrigated fields, where in a few hours they hatch and release the miracidia. The 
latter penetrate and parasitise certain snails that inhabit the fresh water and constitute the 
intermediary host. Each species of Schistosoma parasitises a particular genus of snail, as 
follows: 
- S. Haematobium: Bulinus, Physopis, Planorbis. 
- S. mansoni: Biomphalaria. 
- S. japonicum: Oncomelania. 
- S. mekongi: Tricula aperta. 
- S. intercalatu: Bulinus. 
- S. malayensis: Tricula aperta. 
Within the snail, they mature for approximately 6 weeks to become cercariae (with a 
bifurcated tail and penetration glands), which are then released back into the water. 
Humans can become infected by walking, bathing or washing in water contaminated by 
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cercariae, which adhere to the skin and penetrate it. In this process, they lose their tails and 
are transformed into schistosomulae, which reach the bloodstream and are  systemically 
distributed, reaching the lungs and finally the liver, where they mature into the adult form 
and attach themselves in their definitive location, the mesenteric or vesical venous plexuses, 
and thus the cycle is completed. The period between the cercariae penetrating the skin and 
the beginning of egg production from adult worms is 4-7 weeks. Adult worms can live in 
the venous plexuses for 20-30 years. Direct transmission between persons does not take 
place, as the participation of the snail in the biological cycle of this trematode is absolutely 
necessary. 
3. Geographic distribution 
Schistosomiasis is the second most prevalent tropical disease, after malaria, and has been 
included in the World Health Organisation list of ‘forgotten’ tropical diseases. Its 
geographic distribution varies according to the species of Schistosoma, but it is endemic in 74 
countries. Recent studies have calculated that over 95% of cases are concentrated in Africa, 
especially in sub-Saharan Africa (80%), which is explained by the particular socio-ecological 
conditions prevailing in these areas, with widespread poverty and a virtual absence of 
populational health systems. Other endemic areas include Central and South America, the 
Middle East, and SE Asia (Gryseels et al., 2006). 
Worldwide, 800 million people are at risk and over 200 million have been infected, most 
of them in poor communities without access to clean drinking water or adequate 
sanitation. Of these, 20 million suffer severe consequences of the infection, although, on 
the other hand, 120 million are asymptomatic. It has been estimated that intestinal 
schistosomiasis causes, in Africa alone, over 200,000 deaths a year (130,000 due to portal 
hypertension). 
These are agricultural populations, where contact with infected fresh water occurs 
constantly, when people walk in stagnant water, or swim in rivers or lakes. The construction 
of new dams and the extension of irrigation systems are known to multiply the risk of 
contracting this disease (Steinmann et al., 2006). Children, who may play in infected water, 
and who often suffer a hygiene deficit, are particularly vulnerable. Also at risk are women 
who carry out domestic tasks such as washing clothes in these waters. It has been estimated 
that in chronic cases of vaginal schistosomiasis, the risk of HIV infection is multiplied three-
fold (Ndhlovu et al., 2007). 
The WHO strategies for controlling schistosomiasis are centred on reducing cases of the 
disease via periodic, focused treatment with praziquantel. This is a cheap and effective drug, 
costing only €0.08 per dose. Nevertheless, it may still be expensive for the health 
administrations of some developing countries. Outbreaks of schistosomiasis can be 
identified by haematuria screening of schoolchildren and, in cases of epidemic, treating the 
entire community at risk. Annual doses of praziquantel are sometimes recommended in 
these areas at high risk of re-infection, and contribute to reducing the severity of symptoms 
among the chronically sick, and minimising the consequent multi-organ dysfunction. In 
Egypt, China and Uganda, in just a few years, this approach has reduced the prevalence and 
intensity of parasitisation, and anaemia (Global Network for Neglected Tropical Diseases; 
Hotez et al 2010). 
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Therefore, the international community must be made aware of the social and economic 
magnitude of the problem. International donations are urgently needed to control this 
disease, which by its prevalence and severity is greatly hampering the economic advance 
and sustainable development of many African countries (Baker et al., 2010). Nevertheless, 
praziquantel is not a panacea, and actions in endemic countries should also include 
integrated strategies aimed at the identification, monitoring and surveillance of these 
tropical diseases which, because they are so infrequent in developed countries, are 
frequently overlooked or ignored (Utzinger et al., 2010). This is the background to the 
creation of the Global Network for Neglected Tropical Diseases, an initiative aimed at 
supporting developing countries in their fight against ‘forgotten’ diseases that affect 1400 
million people all over the world. This organisation was inaugurated in 2006 and has its 
headquarters at the Sabin Vaccine Institute in Washington. 
In Africa, refugee movements and migration toward cities, as well as to countries in the 
developed world, are introducing this disease into previously unaffected areas. Increasing 
population numbers and the corresponding greater demand for energy and water often give 
rise to development plans and environmental actions that also contribute to increasing the 
transmission of the disease. The boom in ecotourism and journeys outside controlled areas 
are also provoking an increase in the number of tourists with imported schistosomiasis, 
among all the neglected tropical diseases (López-Vélez  et al, 2008).  
The GeoSentinel Surveillance Network carried out a transversal study of affected 
travellers who had visited endemic schistosomiasis areas between 1997 and 2008. 
Confirmed cases were communicated in 12 countries belonging to this worldwide 
surveillance network. In a total sample of 25,240, some 410 persons (16 per thousand) 
were found to be suffering from schistosomiasis; 37% were European, 24% North 
American, 24% Asian and 15% from Oceania. Over 80% of those affected had acquired 
this disease in Africa, mainly in sub-Saharan Africa. There were some differences 
depending of demographic characteristics and the type of travel. Male travelers and 
travelers < 45 years of age were more likely to be diagnosed with schistosomiasis relative 
to another illness. When the data were controlled for age and sex, those traveling for 
missionary or other volunteer work were twice as likely to be diagnosed with 
schistosomiasis as were tourist and other types of travelers. Business travelers were less 
likely to be diagnosed with schistosomiasis than were tourists and other types of 
travelers. Individuals traveling as expatriates, regardless of the type of travel, were twice 
as likely to be diagnosed with schistosomiasis as those staying for shorter times and 
staying in hotels. Having a pre-travel consultation was also associated with being 
diagnosed with schistosomiasis. Sixty-three percent of the 401 ill returned travelers with 
schistosomiasis presented to a GeoSentinel clinic within six months after travel with a 
median time-to-presentation of six weeks (IQR 2–12 weeks; The median duration of travel 
for this group was 13 weeks (IQR 4–33 weeks). One hundred ten (27%) travelers presented 
to a GeoSentinel clinic more than 6 months after travel. Time-to-presentation was between 
6 months and two years for 73 (18%), three to four years for 16 (4%), and five or more 
years for 18 (4%). 41% of the 319 travelers who were asymptomatic at presentation, were 
diagnosed with schistosomiasis. The most commonly reported symptoms Gastrointestinal 
symptoms were fever, genitourinary symptoms, and fatigue. Returned travelers with 
schistosomiasis were more likely to present with fever than those who were ruled-out for 
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schistosomiasis. Those with S. haematobium and S. mansoni infections presented with more 
respiratory symptoms than did those ruled-out for schistosomiasis. Moreover, returned 
travelers with schistosomiasis who were seen within six months of travel more often 
presented with fever and respiratory symptoms compared with those who presented later 
(Nicolls et al., 2008).  
Imported travel-related infections were studied in a retrospective and descriptive study of 
travelers returning from the tropics and attended at the Tropical Medicine Unit, Infectious 
Diseases Department of Hospital Ramon y Cajal in Madrid (Spain) during the period 
January 1989 to November 2006. The total number of ill travelers analyzed was 2,982; 1387 
traveled to Sub-Saharian Africa and 44 of them were diagnosed with schistosomiasis (3%). A 
total of 98% of patients with schistosomiasis had traveled to Sub-Saharian Africa and only 
2% to other geographical areas. (Zamarrón et al, 2010) 
Many centres in Australia routinely screen African refugees for schistosomiasis using 
serology, and in some cases with faeces and urine examination for schistosome ova. There 
were a seroprevalence of 38% for 653 African refugee adults and children arriving in 
Australia, predominantly from Liberia, Burundi, Tanzania and Sudan. A multivariate 
analysis of the Newcastle data showed that schistosomiasis serology was much more 
likely to be positive in those from East Africa (OR 14.5) and West Africa (OR 5.5) than 
from the Sudan region (OR 1.0). (Davis et al., 2007) In those who had faeces and urine 
examination in these cohorts, urinary schistosomiasis is uncommon, with >95% of those 
with positive microscopy having S. mansoni in faeces (Australasian Society for Infectious 
Diseases, 2009). 
4. Clinical signs  
The clinical manifestations of the disease are produced by the body's inflammatory reaction 
to the eggs and larvae, as the adult worm eludes the humeral and cell-mediated immune 
response. In the blood vessels, attempts at migration through the walls may produce 
haemorrhages and inflammatory processes. When larvae become lodged in the intestinal or 
vesical tissues, they may provoke granulomas, which in time become calcified. In the 
intestinal forms, some of the eggs are transported to the portal venous plexuses and may 
become trapped in the liver, producing periportal fibrosis. 
4.1 Acute schistosomiasis 
In the cercariae entry zone, pruriginous skin lesions of a macular or macular-papular type 
may appear, the so-called “swimmer’s itch". In persons who have previously been exposed 
and therefore are sensitised, itching may persist and wheals may be suffered for some days. 
In endemic zones, this cercarial dermatitis may remain unnoticed. 
Katayama fever is a systemic hypersensitivity reaction that appears at 2 to 6 weeks after 
exposure to and penetration by the cercariae. It is relatively infrequent among the endemic 
population (due to infradiagnosis or intrauterine sensitisation) and more common among 
persons who have not been previously exposed, such as tourists who come into contact with 
contaminated water. It is provoked mainly by the species S. mansoni and S. japonicum, and 
less frequently so by S. haematobium. The most obvious symptoms coincide with the egg-
depositing phase and consist of fever, shivering, swollen lymph nodes, headaches, 
abdominal pain, bloody diarrhoea and painful swelling of the liver. In addition, respiratory 
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symptoms such as coughing, chest pain or breathing difficulties are often encountered. This 
process is normally self-limiting in time, with a progressive improvement after several 
weeks. Only complications derived from massive infestation may lead to death 
(approximately 0.5% of symptomatic cases). 
4.2 Chronic schistosomiasis 
Lesions arising from chronic infection are due to eggs that remain trapped in the tissues 
over a long period of time. These eggs release proteolytic enzymes that typically provoke 
eosinophilic and granulomatous inflammatory reactions, which are progressively 
followed by fibrotic deposits. This commonly affects individuals who are continually 
exposed to infection in poor rural areas. Apart from digestive or urinary manifestations, 
other less common locations have been reported, such as the lungs, the genitals or the 
brain. 
Among children, the clinical presentation of chronic schistosomiasis varies widely, 
although cases with a high degree of parasitisation normally present anaemia, 
malnutrition and delayed growth. Many of these paediatric cases are reversible with 
appropriate treatment. Moreover, the vertical transmission of the disease by pregnant 
women has been reported. 
4.3 Urogenital schistosomiasis 
This condition is produced solely by the species S. haematobium. Haematuria is a classical, 
initial sign of urogenital schistosomiasis. In advanced cases, a frequent sign is urinary-
bladder fibrosis, which may in turn provoke hydronephrosis. Symptoms and signs 
include dysuria, urgent urination, terminal microscopic and macroscopic haematuria, 
secondary urinary infections and non-specific pelvic pain. Approximately half of all 
infected children develop moderate-severe pathology of the urinary tract, including 
pyelonephritis, urethral hydronephrosis, vesical pseudo-papillomas, nephrotic syndrome, 
etc. Women with urogenital schistosomiasis may present genital lesions, vaginal 
haemorrhages, dyspareunia or vulvar nodules. Vaginal alterations provoked by chronic 
schistosome infection may triple the risk of HIV infection. Among men, it may cause 
disorders of the seminal vesicles and of the prostate and consequent male infertility. 
Chronic renal insufficiency and squamous cell carcinoma of the bladder are other possible 
long-term complications. 
4.4 Intestinal schistosomiasis 
This is produced by the species S. mansoni, S. japonicum, S. intercalatum and S. mekongi. The 
areas where it is most commonly found are the mucous membranes of the large intestine 
and the rectum, where it produces a granulomatous inflammation, with pseudopolyps and 
microulcerations. Clinical manifestations include colicky abdominal pain, diarrhoea and, 
sometimes, gastrointestinal blood loss. 
4.5 Hepatic schistosomiasis  
Hepatic alterations may range from mild inflammation to severe fibrosis. The initial 
inflammation appears as a periportal pre-sinusoidal reaction to the presence of the eggs and 
is an important cause of hepatomegaly among children and adolescents (it appears in up to 
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80% of infected children). In the initial stages, most cases remain asymptomatic. Chronic 
hepatic schistosomiasis or fibrosis develops years after the original infection and is found 
more in young adults with intensive, long-term infections and perhaps a certain degree of 
genetic predisposition. It is the result of a massive deposit of collagen in the periportal 
spaces, which produces pipe-shaped pathognomonic periportal fibrosis, as described by 
Symmer (5-10% of patients). In advanced phases, hepatomegaly is frequent, as are ascites 
and portal hypertension, which with their secondary complications may lead to death (King 
and Dangerfield-Cha, 2008). Associated with these cases, in addition, may be splenomegaly, 
esophageal varices and severe haematemesis.  
Sometimes other organs are compromised by the systematic embolisation of eggs or 
following anomalous migration of the adult schistosome. In the lungs, it is not uncommon 
for this to cause coughing, breathing difficulties and, finally, pulmonary hypertension or 
cor pulmonale. In the nervous system, the medulla may be the site of infection by S. 
mansoni or S. haematobium, provoking transverse myelitis or affecting the medullary cone 
and the cauda equina. Encephalic effects are only produced by S. japonicum and usually 
involve epileptic symptoms or diffuse encephalitis, following the formation of cerebral 
granulomas. 
5. Diagnosis 
In Spain and in other countries bordering the Mediterranean, immigration has increased in 
recent years. According to data published by the Spanish National Institute of Statistics, in 
the year 2000 the immigrant population constituted 2.7% of the population, while in 2007, 
there were 4.5 million immigrants, making up 12.7% of the population. Over 50% of the 
immigrant population comes from areas with a high prevalence of schistosomiasis: 39% 
from Latin America and 14% from sub-Saharan Africa (Instituto Nacional de Estadística, 
2010). In Spain and other European countries, the absence of intermediate hosts, together 
with generally good healthcare conditions, makes infection here almost impossible, and 
there is no risk of transmission within the population. The high prevalence of 
schistosomiasis in some countries in sub-Saharan Africa, together with rising rates of 
immigration, has led to more and more cases of urinary schistosomiasis being reported in 
many European countries. Investigation of cases of long-term haematuria often reveals a 
background of journeys to endemic areas, and in such cases a fresh urine examination may 
be requested. These data demonstrate the need to consider schistosomiasis in the differential 
diagnosis of hematuria in daily practice in primary care in developed countries. There are 
references to urinary schistosomiasis among immigrants arriving from endemic areas or 
following prolonged stays in the above countries, involving contact with contaminated 
water (Uberos et al., 2010). 
During the stage of larval invasion or migration, clinical symptoms respond to the laying of 
eggs and the formation of soluble antigens. This is characteristic of S. mansoni and may last 
up to three months. It is characterised by periportal fibrosis, portal hypertension and 
enlargement of the liver and spleen, with high fever, fatigue, urticaria, swollen lymph nodes 
and eosinophilia. There may also be abdominal pain, weight loss and diarrhoea. The 
presence of eosinophilia among the immigrant population is almost always due to infection 
by helminths (Corachan, 2002). Eosinophilia is defined as a total eosinophil count exceeding 
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440x106/ml. Various studies (Bierman et al., 2005) have estimated that eosinophilia affects 
40-65% of patients. When the egg-laying stage is attained, the clinical pattern is 
characterised by fever, coughing, shivering, urticaria, abdominal pain, adenopathy and 
enlarged spleen, which occurs at 1 to 2 months following infection and may last for over 3 
months. This symptomatic complex is known as the Katayama syndrome. 
Months or years after the beginning of parasitisation there may occur granulomatous 
reactions and fibrosis in the organs affected, including mild effects in the gastrointestinal 
tract with epigastralgia and diarrhoea, or chronic polyps, bloody diarrhoea, haematemesis 
and enlarged spleen. In the urogenital tract, S. haematobium is associated with haematuria, 
pollakiuria, suprapubic pain and thickening of the vesical wall, hydroureter or 
hydronephrosis. Cases of neuroschistosomiasis have also been reported. Histological lesions 
of the schistosomes result from the deposition of eggs in the tissues, where they may 
provoke the formation of granulomas, hyperplasia of the mucous membranes and the 
formation of nodules and polyps that tend to ulcerate and bleed. 
In many cases, there is haematuria, with the emission of several drops of fresh blood at the 
end of every urination. In general, no fever or dysuria is reported. In Spain, the existence of 
parasitisation by S. haematobium is frequently revealed when patients seek treatment for 
persistent haematuria, which is addressed by serial urine culture and empirical antibiotic 
treatment. In these cases, careful consideration of the patient's background, together with 
evidence of journeys made in recent months to endemic zones, should guide the physician’s 
diagnosis. 
Classic parasitological techniques (analysis of sediment) are available to any laboratory, are 
easy and cheap, but time consuming and require experience of the observer. They also have 
a low sensitivity for diagnosis. Direct parasitological diagnosis is performed by examination 
of eggs in the faeces (the Kato-Katz technique) or in 24-hour urine. The presence of eggs in 
the intestinal mucosa may also be investigated, by biopsy. At present, the Kato-Katz 
technique is the most frequently recommended, and this is preferred by the WHO both for 
individual diagnostic studies and for epidemiological investigation. Moreover, it is used to 
determine the prevalence and intensity of soil-transmitted helminthiasis. In addition, it is 
useful for establishing the relation between the number of eggs in the faeces and the 
quantity of adult parasites in the infected host. This information is essential for determining 
the parasite load in the patient. 
Schistosomiasis may be hard to diagnose in patients with a low parasite load and scant 
excretion of eggs, when microscope identification is difficult. Live parasites produce and 
excrete many protein compounds in the different phases of the parasitic cycle. 
Immunodiagnostic techniques are based on the detection of these proteins or antibodies 
formed against them, being more sensitive than conventional ones. The detection of 
circulating antigens difference between active and past infection, and correlate with the 
intensity of infection, morbidity and severity. 
Serological diagnosis may be useful for cases of acute schistosomiasis in areas where it is 
not endemic (Tarp et al., 2000). When serological results are positive, another search for 
Schistoma eggs should be made. When the results of the serological examination are 
negative, it can be assumed that in non-endemic areas the risk of schistosomiasis is very 
low. The determination of antibodies allows early diagnosis of the disease. While not 
opposed to an actual infection of another pass, since the antibodies can be kept at high 
titers for months or even years. Serology requires a period of six weeks for positivisation. 
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Serological diagnosis can be carried out using indirect immunofluorescence techniques 
and ELISA. The following in vivo precipitation techniques are applied: 
a. Vogel-Minning technique (circum-cercarial precipitin test - CCPT). With this technique, 
the cercariae are brought into contact with the patient's serum. If the serum produces 
specific antibodies, the presence of a highly specific precipitate can be observed, due to 
the intervention of cercarial metabolic antigens.  
b. Oliver-Gonzalez technique (circum-oval precipitin test - COPT). This technique is 
identical to the previous one, except that live eggs are used. 
By means of these techniques, it is possible to determine the evolution of the disease. For 
example, for recent schistosomiasis, the CCPT technique is used. 
Image testing (ultrasound imaging, urography, etc.) can be very useful. For digestive 
schistosomiasis, rectal or liver biopsy and colonoscopy may also be useful. Most methods 
used to evaluate the success of interventions, such as egg counting, measure the level of 
infection but do not provide direct evidence of the pathological changes induced by the 
infection. Ultrasound is an excellent tool for assessing the secondary pathological alterations 
produced by the infection. The prevalence and severity of the pathological lesions detected 
by ultrasound are related to the intensity of the infection, evaluated by the quantity of eggs 
eliminated in the faeces or urine. In endemic zones, the maximum rate of morbidity is 
observed among children aged 7-14 years, while in non-endemic zones, the disease is 
diagnosed in all series following an evolution of 2-3 months. The lesions most often 
diagnosed by ultrasound include hydronephrosis, the presence of intravesical masses, 
thickening of the bladder wall and calcification, with the appearance of hydronephrosis 
being associated with the poorest prognosis. Some series have identified lesions to the 
female genital apparatus, with masses identifiable by ultrasound examination. An 
association has been shown between epidermoid carcinoma of the bladder and S. 
haematobium (Corachan, 2002). 
Ultrasound may be useful for diagnosing periportal fibrosis and portal hypertension 
(dilation of the portal and splenic veins and the portosystemic collaterals). Treatment for 
intestinal schistosomiasis generally produces an improvement in the signs of infection, 
including reduced bloody diarrhoea, intestinal polyposis, hepatosplenomegaly and 
periportal fibrosis. 
6. Treatment 
Following confirmation of urinary schistosomiasis, the treatment normally prescribed is oral 
praziquantel at a dose of 600 mg/12 h, in two doses. The analytical analysis is repeated, 15 
days following this treatment, by determining the eosinophil count in blood and by a serial 
examination of fresh urine samples, on three consecutive days, with the presence of S. 
haematobium in urine being discounted when haemogram results are normal. S. haematobium 
is the most frequent cause of haematuria in countries where this disease is endemic. All 
protocols for treating immigrant children include the search for S. haematobium when 
persistent haematuria is reported. We believe this search should be expanded to cases of 
persistent haematuria when there is a case history of bathing or swimming in rivers in zones 
endemic for S. haematobium. The existence of haematuria is related with the presence of 
viable eggs in the bladder wall, which in long-term processes is in turn related with the 
presence of granulomas in the vesical submucosa and the distal part of the urethra 
(Tzanetou et al., 2007). In cases of repeated, severe infection, the urethral mucosa are also 
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affected, and this may evolve to obstructive uropathology and hydronephrosis. The 
preferred treatment in this case is praziquantel at a dose of 40 mg/kg/day, in two doses at 
intervals of 12 hours. At this dose, the cure rate at six weeks is 88%. The administration of a 
second dose of praziquantel at 4-6 weeks increases the cure rate to 100% (Midzi et al., 2008). 
To prevent resistance, some authors recommend a dose of praziquantel at 60 mg/kg/8 h, 
for three days (Botros et al., 2005). During their immature stages, the schistosomes are 
moderately resistant to praziquantel, becoming more sensitive on maturity, when the eggs 
are laid. This means that during the first 10-12 weeks following infection by S. haematobium, 
praziquantel may not be effective (Botros et al., 2005). As an alternative treatment for S. 
haematobium, metrifonate or niridazol may be applied. 
Metrifonate is a reversible competitive inhibitor of the acetylcholinesterase enzyme, 
including the human enzyme. As such, it is a parasympathetic mimetic agent that 
prolongs the action of the parasympathetic nervous system, and in which the 
neurotransmitter is acetylcholine. It performs selective, variable schistosomocidal 
activity against S. haematobium, provoking its partial metabolisation into dichlorvos, an 
active anti-cholinesterase compound. The cholinesterase of the schistosome is more 
susceptible to this metabolite than that of the human host, but at the recommended 
treatment dose, transitory reductions in cholinesterase activity, both in plasma and in 
erythrocytes can be observed. Despite early concerns expressed about its possible 
toxicity, metrifonate is well tolerated and has been widely employed, with good results 
in important treatment programmes. A dose of 7.5 mg/kg, taken on three occasions, at 
intervals of two weeks, produces a 40-80% cure rate. Mass chemotherapy should not be 
undertaken in communities recently exposed to insecticides or other agricultural 
chemicals with an anti-cholinesterase action. Treated patients should not be given 
depolarizing neuromuscular blocking agents such as suxamethonium until at least 48 
hours have elapsed from the time of metrifonate administration. If necessary, to 
alleviate the symptoms of cholinergic activity, atropine sulphate can be used as a 
specific antidote (for adults, 1 mg every six hours). This measure does not impair the 
anti-parasitic action. 
Niridazol is absorbed slowly from the gastrointestinal tract in 10-15 hours. It metabolises 
rapidly during its first pass through the liver, and its metabolites are eliminated in equal 
quantities in the urine and faeces. Schistomocidal activities are produced because niridazol 
is not metabolised in the blood. The normal dose for adults infected with S. haematobium or 
S. mansoni is 25 mg/kg/day, for seven days. For children infected with S. haematobium, the 
treatment duration may be reduced to 5 days if a daily dose of 30-35 mg/kg is administered. 
Children infected with S. mansoni should be treated with 25 mg/kg/day for seven days. In 
bilharziasis caused by S. japonicum, the daily dose for both adults and children is 20-25 
mg/kg for five days. 
As the recommended treatment for intestinal schistosomiasis (S. mansoni), both in the 
acute phase and when the liver and spleen are affected, we propose oxamniquine. This 
is a tetrahydroquinoline derivative with selective, variable schistosomocidal activity 
against S. mansoni. Male schistosomes are more susceptible than females, but the 
females that survive cease to lay eggs after exposure to oxamniquine and become 
irrelevant from a pathological standpoint. Some varieties are resistant, especially in 
South America, although these respond to subsequent treatment with praziquantel. 
Oxamniquine is well absorbed when administered orally and generally metabolises to 
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inactive acid metabolites that are eliminated in the urine. It is well tolerated and has 
been widely used with good results in control programmes carried out in South 
America. 
7. Control measures against schistosomiasis 
The aim of control programmes is to reduce morbidity. In 1922, after the discovery of  
the role played by snails in transmission of the disease, strategies were developed 
consisting in the primary control of snails in highly endemic areas. From 1960, new 
technologies were discovered to achieve the same goal; on the one hand, niclosamide, 
was applied to eliminate the snails, and on the other, praziquantel was found to be a 
safe treatment option with few secondary effects. Countries such as Egypt, with high 
rates of endemic schistosomiasis, have developed control programmes including annual 
checkups for school-age children and treatment for all suspected cases, together with 
programmes to control snail infestation by the drainage and cleaning of all rivers and 
canals (Salem et al., 2011). Thanks to these measures, by the end of 2002, the prevalence 
of S. mansoni had been reduced to 2.7%, from the value of 14.8% recorded in 1993. 
Similarly, the prevalence of S. haematobium fell from 6.6% in 1993 to 1.2% in 2006. This 
method reduced morbidity, but in other areas, improved water supply has also led to 
low levels of prevalence. 
In countries of origin, it seems reasonable that the primary objective in the control of 
schistosomiasis consists in reducing morbidity, or at least severe forms of the disease. The 
imported forms of the disease appears early diagnosis key to disease, in environments 
where the low prevalence of the disease complicates the diagnosis. The importance of 
history, focusing on the existence of previous residence or travel in endemic areas seems 
essential. 
In the communities of African immigrants, is often found that more than one family 
member is parasitized and hematuria, if not too intensive, is an inconspicuous sign for the 
patient or their relatives. This fact illustrates the need to subject these patients to a series of 
systematic reviews of health in destination countries to establish not only the diagnosis of 
imported diseases as the present one, but also those others present in our midst and very 
frequent in the geographic area of origin. 
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